


CLAIMS

1. A compound of formula (I):



(I)

wherein:

**Ring A** is imidazo[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl;

**R<sup>2</sup>** is attached to a ring carbon and is selected from halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkanoyl, C<sub>1-6</sub>alkanoyloxy, N-(C<sub>1-6</sub>alkyl)amino, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>amino, C<sub>1-6</sub>alkanoylamino, N-(C<sub>1-6</sub>alkyl)carbamoyl, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-6</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-6</sub>alkoxycarbonyl, N-(C<sub>1-6</sub>alkyl)sulphamoyl, N,N-(C<sub>1-6</sub>alkyl)<sub>2</sub>sulphamoyl, phenyl, heterocyclic group, phenylthio or (heterocyclic group)thio; wherein any C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, phenyl or heterocyclic group may be optionally substituted on carbon by one or more G; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from Q;

**m** is 0-5; wherein the values of R<sup>2</sup> may be the same or different;

**R<sup>1</sup>** is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C<sub>1-3</sub>alkyl, C<sub>2-3</sub>alkenyl, C<sub>2-3</sub>alkynyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkanoyl, N-(C<sub>1-3</sub>alkyl)amino, N,N-(C<sub>1-3</sub>alkyl)<sub>2</sub>amino, C<sub>1-3</sub>alkanoylamino, N-(C<sub>1-3</sub>alkyl)carbamoyl, N,N-(C<sub>1-3</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-3</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, N-(C<sub>1-3</sub>alkyl)sulphamoyl or N,N-(C<sub>1-3</sub>alkyl)<sub>2</sub>sulphamoyl; wherein any C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkyl, C<sub>2-3</sub>alkenyl or C<sub>2-3</sub>alkynyl may be optionally substituted on carbon by one or more J;

**n** is 0 to 2, wherein the values of R<sup>1</sup> may be the same or different;

**Ring B** is phenyl or phenyl fused to a C<sub>5-7</sub>cycloalkyl ring;

**R<sup>3</sup>** is halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C<sub>2-6</sub>alkenyl or C<sub>2-6</sub>alkynyl;

- 74 -

p is 0-4; wherein the values of  $R^3$  may be the same or different;

$R^4$  is a group A-E; wherein

A is selected from  $C_{1-6}$ alkyl, phenyl, a heterocyclic group,  $C_{3-8}$ cycloalkyl, phenyl $C_{1-6}$ alkyl, (heterocyclic group) $C_{1-6}$ alkyl or  $C_{3-8}$ cycloalkyl $C_{1-6}$ cycloalkyl; which

5  $C_{1-6}$ alkyl, phenyl, a heterocyclic group,  $C_{3-8}$ cycloalkyl, phenyl $C_{1-6}$ alkyl, (heterocyclic group) $C_{1-6}$ alkyl or  $C_{3-8}$ cycloalkyl $C_{1-6}$ cycloalkyl may be optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R;

10 E is a direct bond or -O-, -C(O)-, -OC(O)-, -C(O)O-, -N( $R^a$ )C(O)-, -C(O)N( $R^a$ )-, -N( $R^a$ )-, -S(O)<sub>r</sub>-, -SO<sub>2</sub>N( $R^a$ )- or -N( $R^a$ )SO<sub>2</sub>-; wherein  $R^a$  is hydrogen or  $C_{1-6}$ alkyl optionally substituted by one or more D and r is 0-2;

15 D is independently selected from oxo, halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{1-6}$ alkoxy,  $C_{1-6}$ alkanoyl,  $C_{1-6}$ alkanoyloxy,  $N$ -( $C_{1-6}$ alkyl)amino,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>amino,  $C_{1-6}$ alkanoylamino,  $N$ -( $C_{1-6}$ alkyl)carbamoyl,  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>carbamoyl,  $C_{1-6}$ alkylS(O)<sub>a</sub> wherein a is 0 to 2,  $C_{1-6}$ alkoxycarbonyl,  $C_{1-6}$ alkoxycarbonylamino, benzyloxycarbonylamino,  $N$ -( $C_{1-6}$ alkyl)sulphamoyl and  $N,N$ -( $C_{1-6}$ alkyl)<sub>2</sub>sulphamoyl; wherein any  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl or phenyl may be optionally substituted on carbon by one or more K;

20 q is 0-2; wherein the values of  $R^4$  may be the same or different; and wherein  $p + q \leq 5$ ;

G, J and K are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxyl, methylamino, ethylamino, dimethylamino, diethylamino,  $N$ -methyl- $N$ -ethylamino, acetylamino,  $N$ -methylcarbamoyl,  $N$ -ethylcarbamoyl, 25  $N,N$ -dimethylcarbamoyl,  $N,N$ -diethylcarbamoyl,  $N$ -methyl- $N$ -ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl,  $N$ -methylsulphamoyl,  $N$ -ethylsulphamoyl,  $N,N$ -dimethylsulphamoyl,  $N,N$ -diethylsulphamoyl or  $N$ -methyl- $N$ -ethylsulphamoyl; and

30 Q and R are independently selected from  $C_{1-4}$ alkyl,  $C_{1-4}$ alkanoyl,  $C_{1-4}$ alkylsulphonyl,  $C_{1-4}$ alkoxycarbonyl, carbamoyl,  $N$ -( $C_{1-4}$ alkyl)carbamoyl,  $N,N$ -( $C_{1-4}$ alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

2. A compound of formula (I) according to claim 1 wherein R<sup>1</sup> is bromo or 2-hydroxyethylthio and n is 0-1;  
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

5

3. A compound of formula (I) according to any of claims 1 or 2 wherein Ring A is imidazo[1,2a]pyrid-3-yl;  
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

10 4. A compound of formula (I) according to any of claims 1 - 3 wherein R<sup>2</sup> is attached to a ring carbon and is selected from fluoro, chloro, bromo, cyano, methyl, methoxy, ethylthio, 2-hydroxyethylthio or 2-dimethylaminoethylthio and m is 0-2; wherein the values of R<sup>2</sup> may be the same or different;  
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

15

5. A compound of formula (I) according to any of claims 1 - 4 wherein R<sup>3</sup> is fluoro, chloro, bromo or sulphonamoyl; and p is 1;  
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

20 6. A compound of formula (I) according to any of claims 1 - 5 wherein R<sup>4</sup> is methyl, ethyl, methoxy, methylthio, acetyl, benzoyloxy, mesyl, *N,N*-diethylaminoethoxy, 3-*N,N*-dimethylamino-2-hydroxypropoxy, phenoxy, *N*-methylcarbamoyl, *N,N*-dimethylcarbamoyl, *N*-(3-imidazol-1-ylpropyl)carbamoyl, *N*-[3-(2-oxo-pyrrolidin-1-yl)propyl]carbamoyl, 3,5-dioxapiperidin-1-ylsulphonyl,  
25 *N*-cyclopropylsulphonamoyl, *N*-cyclopropylmethylsulphonamoyl, anilinosulphonyl, *N*-pyrimidin-2-ylsulphonamoyl, *N*-methylsulphonamoyl, *N*-propylsulphonamoyl, *N*-(2-methoxyethyl)sulphonamoyl, *N*-(2-methylaminoethyl)sulphonamoyl, *N*-(2-isopropylaminoethyl)sulphonamoyl, *N*-(2-dimethylaminoethyl)sulphonamoyl, *N*-(2-diethylaminoethyl)sulphonamoyl, *N*-[2-(hydroxyethylamino)ethyl]sulphonamoyl,  
30 *N*-[2-(diethylaminoethyl)ethyl]sulphonamoyl, *N*-(pyrrolidin-1-ylethyl)sulphonamoyl, *N*-[2-(1-methylpyrrolidin-2-yl)ethyl]sulphonamoyl, *N*-(2-piperidin-1-ylethyl)sulphonamoyl, *N*-(2-piperazin-1-ylethyl)sulphonamoyl, *N*-(2-morpholinoethyl)sulphonamoyl,

- 76 -

*N*-(2-imidazol-4-ylethyl)sulphamoyl, *N*-(3-hydroxypropyl)sulphamoyl,  
*N*-(2,3-dihydroxypropyl)sulphamoyl, *N*-(3-methoxypropyl)sulphamoyl,  
*N*-(3-aminopropyl)sulphamoyl, *N*-(3-methylaminopropyl)sulphamoyl,  
*N*-(3-dimethylaminopropyl)sulphamoyl, *N*-(3-diethylaminopropyl)sulphamoyl,  
5 *N*-(3-isopropylaminopropyl)sulphamoyl, *N*-(3-*t*-butoxycarbonylaminopropyl)sulphamoyl,  
*N*-(3-benzyloxycarbonylaminopropyl)sulphamoyl,  
*N*-[3-(2-oxopyrrolidin-1-yl)propyl]sulphamoyl, *N*-(3-morpholinopropyl)sulphamoyl,  
*N*-[3-(4-methylpiperazin-1-yl)propyl]sulphamoyl, *N*-(3-imidazol-1-ylpropyl)sulphamoyl or  
*N*-(5-hydroxypentyl)sulphamoyl; and *q* is 1;

10 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

7. A compound of formula (I) according to any of claims 1 - 6 wherein Ring B is phenyl;  
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

15 8. A compound of formula (I) selected from:

2-(4-Sulphamoylanilino)-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;

2-[4-(*N*-Methylsulphamoyl)anilino]-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;

2-{4-[*N*-(2-Methoxyethyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;

2-{4-[*N*-(3-Methoxypropyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;

20 2-{4-[*N*-(3-Isopropylaminopropyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)  
pyrimidine;

2-{4-[*N*-(3-Dimethylaminopropyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)  
pyrimidine;

2-{4-[*N*-(2-Dimethylaminoethyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine;

25 2-{4-[*N*-(2-Methylaminoethyl)sulphamoyl]anilino}-4-(imidazo[1,2a]pyrid-3-yl)pyrimidine; or

2-{4-[*N*-(2-Methoxyethyl)sulphamoyl]anilino}-4-[5-(2-hydroxyethylthio)imidazo[1,2a]  
pyrid-3-yl]pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.


30 9. A process for preparing a compound of formula (I) according to claim 1, or a  
pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof, which process

20220610059019

- 77 -


(wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , Ring A, Ring B, m, p, q and n are, unless otherwise specified, as defined in formula (I)) comprises of:

a) reaction of a pyrimidine of formula (II):




(II)

wherein L is a displaceable group; with an amine of formula (III):




(III)

b) reacting a pyrimidine of formula (IV):



(IV)


with a compound of the formula (V):



(V)


15 wherein one of M and Q is a displaceable group X and the other is an metallic reagent Y; or

c) reacting a compounds of formula (VI):



(VI)

with a compound of formula (VII):



(VII)

wherein R<sup>5</sup> is C<sub>1-6</sub>alkyl and R<sup>6</sup> is hydrogen or R<sup>1</sup>;

5 and thereafter if necessary:

- i) converting a compound of the formula (I) into another compound of the formula (I);  
ii) removing any protecting groups;  
iii) forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

10. A pharmaceutical composition which comprises a compound of formula (I) according to any one of claims 1 - 8, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof in association with a pharmaceutically-acceptable diluent or carrier.

11. ~~A compound of the formula (I) according to any one of claims 1 - 8, or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof for use in a method of treatment of the human or animal body by therapy.~~

12. The use of a compound of the formula (I) according to any one of claims 1 - 8, or a pharmaceutically acceptable salt or *in vivo* hydrolyzable ester thereof, in the manufacture of a medicament for use in the treatment of cancers (solid tumours and leukemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation.

~~old~~  
22